Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Active Comparator- IV Antifungal (LAmB or voriconazole)

Phase 2

EElion Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Infection

NCT07215273

Clinical

Trials by Indication[1]

Infection1 trial

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)

Recruiting·EElion Therapeutics, Inc.·Phase 2·NCT07215273·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Active Comparator- IV Antifungal (LAmB or voriconazole). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Active Comparator- IV Antifungal (LAmB or voriconazole). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Elion Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: EElion Therapeutics, Inc.

Related News